Health — 11 October 2013

By Richard Lenti

Good news for people suffering from multiple sclerosis. The results of a long term study show that Tecfidera, the newest multiple sclerosis (MS) drug on the market, remained effective for patients taking the medicine for at least four years with no new safety problems.

The news is also good for the drug’s manufacturer, Massachusetts-based Biogen Idec (NASDAQ: BIIB). Analyst expect sales of the twice-a-day dimethyl fumarate capsules (sold under the brand name Tecfidera) to eventually dominate the MS market.

In its first quarter on the market, the drug had sales of $192 million, nearly triple Wall Street expectations.  Biogen has a 15-year patent on the drug, which costs patients over $4,000 a month.

“Because MS is a chronic, life-long disease, physicians and patients need to know they are taking a treatment that will offer them sustained efficacy over the long-term with a consistent safety profile,” said Doug Williams, executive vice president, Research and Development, Biogen Idec.

“These analyses provide important information on the benefits of Tecfidera’s strong efficacy and favorable safety for a wide range of patients.”

Read more at National Pain Report.


About Author

Pat Anson, Editor

Pat is Editor in Chief of American News Report. He is a veteran journalist and a former correspondent and producer for HealthWeek (PBS), Nightly Business Report (PBS) and other nationally syndicated shows. Pat has won numerous journalism awards, including a Golden Mike award for investigative reporting.

(0) Readers Comments

Comments are closed.